Increased expression of the secretory leukocyte proteinase inhibitor in Wegener's granulomatosis

Clinical and Experimental Immunology

Volumn 131, Issue 1, 2003, Pages 190-196

  Ohlsson, Sophie ^a,d   Falk, R ^b   Yang, J J ^b   Ohlsson, K ^a   Segelmark, M ^a   Wieslander, J ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Ideon Science Park   (Sweden)

^d BMC C14   (Sweden)

Author keywords

Protease inhibitor SLPI vasculitis Wegener's granulomatosis ANCA

Indexed keywords

CREATININE; CYSTATIN; INTERLEUKIN 6; MESSENGER RNA; PROTEINASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; KIDNEY DISEASE; LEUKOCYTE; LEUKOCYTE COUNT; NASAL BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWEDEN; UPREGULATION; WEGENER GRANULOMATOSIS;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKOCYTES; NASAL MUCOSA; PANCREATIC ELASTASE; POLYMERASE CHAIN REACTION; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; RNA, MESSENGER; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; WEGENER GRANULOMATOSIS;

EID: 12244258267     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02024.x     Document Type: Article

References (39)

1. Wegener F. Über eine eigenartige rhinogene granulomatose mit besonderer Beteilgung des Arteriensystems und den Nieren. Beitr Pathol Anat Allg Pathol 1939; 102:36-68.
2. Godman GC, Churg J. Wegener's granulomatosis: Pathology and review of the literature. Arch Pathol 1954; 58:533-53.
3. Segelmark M. Rapidly progressive glomerulonephritis. PhD Thesis. Lund: Lund University, 1995.
4. Segelmark M, Elzouki AN, Wieslander J et al. The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 1995; 48:844-50.
5. Carmichael DF, Ohlsson K. Chemistry and biology of secretory leukoprotease inhibitor. In: Crystal RG, ed. Alpha-1-antitrypsin Deficiency: Biology, Pathogenesis, Clinical Manifestations. New York, Basel, Hong Kong: Mercel Dekker Inc., 1996:193-208.
6. Hiemstra PS, Maassen RJ, Stolk J et al. Antimicrobial activity of anti-leucoprotease. Infect Immun 1996; 64:4520-4.
7. McNeely TB, Shugars DC, Rosendahl M et al. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:1141-9.
8. Bruch M, Bieth JG. Influence of elastin on the inhibition of leucocyte elastase by alpha-1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor. Biochem J 1986; 238:269-73.
9. Sano C, Shimizu K, Sato H et al. Effects of secretory leukocyte protease inhibitor on the production of the anti-inflammatory cytokines IL-10 and transforming growth factor-beta (TGF-β). Clin Exp Immunol 2000; 121:77-85.
10. Maruyama M, Hay JG, Yoshimura et al. Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J Clin Invest 1994; 94:368-75.
11. Bingle L, Tetley TD. Secretory leukoprotease inhibitor: Partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. Thorax 1996; 51:1273-4.
12. Grobmyer SR, Barie PS, Nathan CF et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 2000; 28:1276-82.
13. Sallenave JM, Donnelly SC, Grant IS et al. Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. Eur Respir J 1999; 13:1029-36.
14. Shimoya K, Moriyama A, Ogata I et al. Increased concentrations of secretory leukocyte protease inhibitor in peritoneal fluid of women with endometriosis. Mol Hum Reprod 2000; 6:829-34.
15. Trefz G, Schliesser J, Heck B. Alpha 1-proteinase inhibitor and mucus proteinase inhibitor in human lung emphysema. Clin Invest 1992; 70:269-76.
16. Rao NV, Marshall BC, Gray BH. Interaction of secretory leukocyte protease inhibitor with proteinase-3. Am J Respir Cell Mol Biol 1993; 8:612-6.
17. Bergenfeldt M, Axelsson L, Ohlsson K. Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors. Scand J Clin Laboratory Invest 1992; 52:823-9.
18. Zhang Y, De Witt DL, McNeely TB. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99:894-900.
19. Westin U, Fryksmark U, Polling Å et al. Localisation of secretory leucocyte proteinase inhibitor mRNA in nasal mucosa. Acta Otolaryngol 1994; 114:199-202.
20. Bergenfeldt M et al. Localization of immunoreactive secretory leukocyte protease inhibitor (SLPI) in intestinal mucosa. J Gastroenterol 1996; 31:18-23.
21. Nyström M, Bergenfeldt M, Ljungcrantz I et al. Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells. Med Inflamm 1999; 8:147-51.
22. Ohlsson S, Tufresson B, Polling Å et al. Distribution of the secretory leucocyte proteinase inhibitor in human articular cartilage. Biol Chem 1997; 378:1055-8.
23. Westin U, Polling Ä, Ljungcrantz I et al. Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry andin situ hybridisation. Biol Chem 1999; 380:489-93.
24. Sallenave JM, Si-Tahar M, Cox G et al. Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leukoc Biol 1997; 61:695-702.
25. Ohlsson S, Ljungkrantz I, Ohlsson K, Segelmark M, Wieslander J. Novel distribution of the secretory leucocyte proteinase inhibitor in kidney. Med Inflamm 2001; 10:347-50.
26. Mayet WJ, Marker-Hermann E, Schlaak J et al. Irregular cytokine pattern of CD4+ T lymphocytes in response toStaphylococcus aureus in patients with Wegener's granulomatosis. Scand J Immunol 1999; 49:585-94.
27. George J, Levy Y, Kallenberg CG et al. Infections and Wegener's granulomatosis - A cause and effect relationship? QJM 1997; 90:367-73.
28. Jin FY, Nathan C, Radzioch D et al. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997; 88:417-26.
29. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33-9.
30. Pendergraft WF, Alcorta DA, Segelmark M et al. ANCA antigens, proteinase 3 and myeloperoxidase, are not expressed in endothelial cells. Kidney International 2000; 57:1981-90.
31. Gross WL, Csernok E, Helmchen U. Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis. Apmis 1995; 103:81-97.
32. Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000; 190:349-59.
33. Homer RJ. Antineutrophil cytoplasmic antibodies as markers for systemic autoimmune disease. Clin Chest Med 1998: 19:627-39.
34. Fryksmark U, Jannert M, Ohlsson K et al. Secretory leukocyte protease inhibitor in normal, allergic and virus induced nasal secretions. Rhinology 1989; 27:97-103.
35. Fryksmark U, Prellner T, Tegner H, Ohlsson K. Studies on the role of antileukoprotease in respiratory tract diseases. Eur J Respir Dis 1984; 65:201-9.
36. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1995; 268:L601-6.
37. Dery O, Corvera CU, Steinhoff M et al. Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases. Am J Physiol 1998; 274:C1429-52.
38. Howells GL, Macey MG, Chinni C et al. Proteinase-activated receptor-2: Expression by human neutrophils. J Cell Sci 1997; 110:881-7.
39. Macfarlane SR, Seatter MJ, Kanke T et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53:245-82.